Xinhua Headlines: China considers tougher law against counterfeit drugs

    Source: Xinhua| 2018-10-23 00:05:46|Editor: Yurou
    Video PlayerClose

    Xinhua Headlines: China considers tougher law against counterfeit drugs

    A health insurance staff checks medicines in a pharmacy of the Second Affiliated Hospital of Fujian Medical University in Quanzhou, southeast China's Fujian Province, Aug. 2, 2018. (Xinhua/Wei Peiquan)

    BEIJING, Oct. 22 (Xinhua) -- Chinese lawmakers began reviewing a draft amendment to the Drug Administration Law on Monday, which toughens penalties for offenders as the country cracks down on counterfeit drugs and better regulates the industry.

    The draft, submitted for the first reading at a bi-monthly session of the Standing Committee of the National People's Congress, came a week after Changchun Changsheng, a Chinese pharmaceutical company, was hit with a 9.1 billion yuan (1.31 billion U.S. dollars) fine for producing faulty human rabies vaccines.

    "The revisions highlighted heavier punishments and strengthened whole-process supervision," said Jiao Hong, head of the National Medical Products Administration (NMPA), when presenting the draft to the lawmakers.

    All-ROUND SUPERVISION

    According to the draft, supervision of drugs will be further tightened and expanded to cover the whole process, including raw material supply, manufacturing and pre-sale examination.

    The draft introduces a "full traceability" mechanism and a drug recall system.

    To address problems laid bare by the vaccine scandal, the draft underlines the management and supervision of vaccines.

    It identifies vaccine, blood products and anaesthetic drugs as special medicine products, which are not allowed for sub-contract production, and requires "vaccine license holders" to get their products covered under compulsory insurances.

    Moreover, manufacturers who fail to discover or remove drug safety risks will be subject to suspension of production and sales.

    The draft also proposes a drug safety credit system to timely update and publish drug safety information, including manufacturing permits, results of daily inspections and violations.

    TOUGHER PUNISHMENT

    Though Chinese regulators have strengthened measures in recent years, counterfeit or sub-standard drugs still exist, a problem some industry watchers have attributed to weak punishment.

    Li Jiang, an NMPA legal adviser, said the draft amendment had comprehensively toughened punishments.

    According to the draft, both the lower and upper limits of penalties will be increased. For instance, those who engage in drug manufacturing or selling without a license will be fined five to 30 times their earnings, as opposed to two to five times currently.

    In addition, the draft stipulates several occasions where heavier punishment is applicable, including making and selling faulty vaccines, as well as making and selling counterfeit or sub-standard drugs for pregnant women and children.

    On the Changchun Changsheng case, Li told Xinhua in a previous interview that "serious punishment for the case will serve as a warning for drug safety and shows the authorities' resolution to crack down on drug violations and protect people's health."

    The draft also sets to amplify the personal risks for perpetrators. Those involved in counterfeit drug cases, such as legal representatives of a pharmaceutical company and those directly in charge of manufacturing, will be fined or banned from the industry, according to the draft.

    INCENTIVES

    Aside from clamping down on making and selling counterfeit drugs, the draft aims to spur innovation and reduce inefficiencies by introducing a "marketing authorization holder (MAH)" mechanism.

    The MAH rule, which was introduced by the State Council in a three-year pilot reform in late 2015, expands those eligible to acquire drug manufacturing licenses, from pharmaceutical companies to drug researchers and institutions.

    "The pilot reform has proved that the MAH rule is feasible and productive," said Liu Pei, another NMPA official in charge of policy and regulations, adding they plan to ask for an extension of the pilot program until the draft amendment is adopted.

    The draft amendment, however, adds more stringent rules to the MAH mechanism, such as requiring holders to continue evaluating drug safety and effectiveness even after the drugs hit the market.

       1 2 3 Next  

    KEY WORDS: counterfeit drugs
    EXPLORE XINHUANET
    010020070750000000000000011100001375509571
    主站蜘蛛池模板: 精精国产xxxx视频在线播放| 91天堂素人精品系列全集亚洲| 欧美一线不卡在线播放| 午夜私人影院免费体验区| 欧美另类第一页| 天天影视色香欲综合免费| 久久久久综合国产| 欧美伊人久久大香线蕉综合| 免费看美女隐私全部| 顶级欧美色妇xxxxbbbb| 国产精品观看在线亚洲人成网| 三上悠亚精品一区二区久久| 日韩精品极品视频在线观看免费| 亚洲视频一区网站| 美美女高清毛片视频免费观看| 国产日韩欧美精品一区| 99久久精品国产片久人| 成人福利小视频| 久久精品国产亚洲av不卡| 欧美美女与野兽免费看电影| 动漫毛片在线观看| 青青网在线视频| 国产精品99久久免费观看| 99免费视频观看| 征服人妇系列200| 久久人人爽人人爽人人片AV超碰 | 毛片视频在线免费观看| 卡通动漫中文字幕第一区| 领导边摸边吃奶边做爽在线观看| 国产精品对白刺激久久久| a级精品国产片在线观看| 我就想添50多的老女人水很多| 久草视频在线资源站| 欧美日韩在线视频免费完整| 伊人久久波多野结衣中文字幕 | 精品久久久无码人妻中文字幕| 国产在线视频一区二区三区| 香蕉视频黄在线观看| 天堂草原电视剧在线观看图片高清| 中文字幕人妻无码一夲道| 日本边摸边吃奶边做很爽视频|